Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleExperimental Studies

Molecular Immunological Approaches to Biotherapy of Human Cancers - A Review, Hypothesis and Implications

YECHIEL BECKER
Anticancer Research March 2006, 26 (2A) 1113-1134;
YECHIEL BECKER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: becker@md.huji.ac.il
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The immune system of the human organism comprises the innate system cells and the adaptive immune cells. The former include the hematopoietic cells, mast cells, basophils, monocytes, dendritic cells (DCs) and macrophages, and the latter include CD4+ T cells, CD8+ T cells, T regulatory cells (Tr) and B cells. The innate system DCs are the major antigen-presenting cells to Tho CD4+ T cells in lymph nodes that polarize into T helper 1 (Th1) and T helper 2 (Th2) cells, which subsequently produce different cytokines. Polarized Th1 cells produce interleukin (IL)-2, IL-12 and interferon (IFN)-gamma, and polarized Th2 cells and the hematopoietic cells produce IL-4, IL-5, IL-6, IL-10 and IL-13. In healthy individuals there is a Th1/Th2 cytokine balance, but during microbial-induced inflammation the pathogens induce an overproduction of the Th2 cytokines that inhibit the adaptive immune response against the pathogen. A review of studies on the Th1/Th2 cytokine balance in humans harboring different tumor types revealed that tumor cells induce increased Th2 cytokine levels in patients' sera that can serve as indicators for the existence of tumors. In this review, studies which correlated the presence of increased Th2 cytokines with the presence of early tumors and tumor progression are discussed. It was suggested that early monitoring of human populations for elevated Th2 cytokines may be used to identify individuals at an early stage of tumor development. A hypothesis is presented which suggests that increased Th2 cytokine synthesis in cancer patients, with early and late tumors, may be treated with Th2 cytokine antagonists. This new approach to cancer treatment will be supplemented by co-treatment with CpG oligodeoxynucleotides(ODNs) which reactivate the adaptive antitumor immune respnse. Studies that provide information on the efficiency of CpG ODN treatment of tumors in mice revealed that tumor regression was achieved by inducing Toll-like receptor 9+ plasmacytoid dendritic cells (PDCs) to release large amounts of type I interferons (IFN alpha and beta), which inhibit Th2 cytokine synthesis by hematopoietic cells and CD4+ T cells and enhance Th1 cytokine synthesis and activation of the adaptive immunity. It is hypothesized that Th2 cytokine (IL-4 and IL-6) antagonists may be an effective treatment for cancer patients since cytokine antagonists inhibit the increased Th2 cytokines in patients. Such an approach may replace Th2 cytokine monoclonal antibodies, the current treatment for cancer patients. It is hypothesized that the effective treatment of cancer patients with Th2 cytokine antagonists, combined with CpG ODNs, will lead to the inhibition of Th2 cytokines and reactivation of the Th1-induced antitumor adaptive immunity that will destroy tumor cells and cure cancer patients.

  • Biotherapy
  • immunotherapy
  • review

Footnotes

  • ↵* Presented at the symposium on “Multidrug and Drug Resistance”, a special symposium supported by Action Cost B16 “Reversal of Antibiotic Resistance” at the Seventh International Conference of Anticancer Research, October 25-30, 2004, Corfu, Greece.

  • Received November 8, 2005.
  • Accepted February 1, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 26 (2A)
Anticancer Research
Vol. 26, Issue 2A
March-April 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Immunological Approaches to Biotherapy of Human Cancers - A Review, Hypothesis and Implications
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Molecular Immunological Approaches to Biotherapy of Human Cancers - A Review, Hypothesis and Implications
YECHIEL BECKER
Anticancer Research Mar 2006, 26 (2A) 1113-1134;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Molecular Immunological Approaches to Biotherapy of Human Cancers - A Review, Hypothesis and Implications
YECHIEL BECKER
Anticancer Research Mar 2006, 26 (2A) 1113-1134;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Cytokine Changes in Response to Radio-/chemotherapeutic Treatment in Head and Neck Cancer
  • Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents
  • Prostaglandin E2 Inhibits IFN-{alpha} Secretion and Th1 Costimulation by Human Plasmacytoid Dendritic Cells via E-Prostanoid 2 and E-Prostanoid 4 Receptor Engagement
  • Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines
  • Type 2 Bias of T Cells Expanded from the Blood of Melanoma Patients Switched to Type 1 by IL-12p70 mRNA-Transfected Dendritic Cells
  • Fine-Tuning of the Prediction of Mortality in Hemodialysis Patients by Use of Cytokine Proteomic Determination
  • Cutting Edge: Natural DNA Repetitive Extragenic Sequences from Gram-Negative Pathogens Strongly Stimulate TLR9
  • Google Scholar

More in this TOC Section

  • The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases
  • Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer
  • Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2022 Anticancer Research

Powered by HighWire